We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-19.99%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$887M
AUM Growth
+$16.2M
Cap. Flow
+$129M
Cap. Flow %
14.54%
Top 10 Hldgs %
50.79%
Holding
136
New
23
Increased
31
Reduced
31
Closed
36

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$34.3M
2
AZN icon
AstraZeneca
AZN
+$20.1M
3
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$14.8M
4
VTRS icon
Viatris
VTRS
+$11.4M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$10.3M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$44.9M
2
MRK icon
Merck
MRK
+$22.8M
3
GSK icon
GSK
GSK
+$21.9M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.53M
5
V icon
Visa
V
+$6.06M

Sector Composition

Rank Sector Weight
1 Healthcare 60.28%
2 Technology 12.21%
3 Industrials 2.92%
4 Consumer Discretionary 0.53%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LRMR icon
76
Larimar Therapeutics
LRMR
$397M
$1.88M 0.21%
31,667
-4,166
-12% -$411K
ALNA
77
DELISTED
Allena Pharmaceuticals
ALNA
$1.88M 0.21%
345,199
+50,000
+17% +$431K
PVLA
78
Palvella Therapeutics
PVLA
$1.99B
$1.86M 0.21%
8,750
-2,559
-23% -$794K
ARRY
79
DELISTED
Array Biopharma Inc
ARRY
$1.78M 0.2%
125,000
-270,000
-68% -$4.1M
MTEM
80
DELISTED
Molecular Templates, Inc.
MTEM
$1.62M 0.18%
26,667
– –
APLS
81
DELISTED
Apellis Pharmaceuticals
APLS
$1.54M 0.17%
117,000
-95,470
-45% -$1.46M
UROV
82
DELISTED
Urovant Sciences Ltd.
UROV
$1.41M 0.16%
214,030
+50,000
+30% +$455K
DOVA
83
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$1.4M 0.16%
185,000
+65,000
+54% +$1.05M
MLNT
84
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
$1.28M 0.14%
323,373
– –
CLSD
85
DELISTED
Clearside Biomedical
CLSD
$1.27M 0.14%
79,008
+2,029
+3% +$95.2K
ACGN
86
DELISTED
Aceragen Inc
ACGN
$1.23M 0.14%
26,236
– –
CRVS icon
87
Corvus Pharmaceuticals
CRVS
$1.12B
$1.18M 0.13%
321,430
– –
SVRA icon
88
Savara
SVRA
$1.12B
$833K 0.09%
110,000
-99,596
-48% -$896K
PHXM
89
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$796K 0.09%
12,000
– –
VRCA icon
90
Verrica Pharmaceuticals
VRCA
$89.7M
$791K 0.09%
9,700
-2,000
-17% -$243K
MGTX icon
91
MeiraGTx Holdings
MGTX
$1.09B
$686K 0.08%
+71,159
New +$898K
FSTX
92
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$530K 0.06%
+12,754
New +$574K
KZR
93
DELISTED
Kezar Life Sciences
KZR
$472K 0.05%
2,000
-19,200
-91% -$4.69M
SRRA
94
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$341K 0.04%
6,463
-19,106
-75% -$1.22M
CNST
95
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$281K 0.03%
+70,162
New +$423K
CUE icon
96
Cue Biopharma
CUE
$113M
$235K 0.03%
1,667
+1,000
+150% +$181K
ADVM
97
DELISTED
Adverum Biotechnologies
ADVM
$200K 0.02%
6,336
-1,164
-16% -$47.3K
BNTC icon
98
Benitec Biopharma
BNTC
$402M
$180K 0.02%
471
– –
CLRB icon
99
Cellectar Biosciences
CLRB
$20.5M
$136K 0.02%
292
– –
AAP icon
100
Advance Auto Parts
AAP
$3.35B
– –
-5,336
Closed -$898K
2 3
4
5 6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2018 Portfolio in Review

As of Q4 2018, Sphera Funds Management held 136 positions worth $887M, up 1.9% from $871M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Sphera Funds Management deployed $129M of net new capital in Q4 2018, opening 23 new positions and adding to 31 existing holdings. Its largest new stake was Celgene Corp: 465,000 shares worth $29.8M.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 75% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Merck, an estimated $22.8M trimmed.

  • Sphera Funds Management's largest Q4 2018 buy was Celgene Corp: 465,000 shares worth $29.8M.
  • Sphera Funds Management added most to Viatris in Q4 2018, an estimated $11.4M increase.
  • Sphera Funds Management's biggest Q4 2018 reduction was Merck, cutting an estimated $22.8M.
  • Sphera Funds Management fully exited Johnson & Johnson in Q4 2018, selling an estimated $44.9M.
  • Sphera Funds Management's ten largest holdings make up 51% of its $887M portfolio in Q4 2018.
  • Sphera Funds Management opened 23 new positions and closed 36 in Q4 2018.
  • Sphera Funds Management's portfolio value rose 1.9% quarter-over-quarter to $887M.

Based on Sphera Funds Management's 13F filing for Q4 2018, filed 14 Feb 2019.